PET/CT Imaging for Monitoring Recurrence and Evaluating Response to Treatment in Breast Cancer

Lei, Lei; Wang, Xiaojia; Chen, Zhan-Hong

doi:10.17219/acem/29853

Cited by 21 publications

(19 citation statements)

References 34 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The diagnosis and treatment strategies regarding breast cancer have markedly improved over previous years, however patients currently still exhibit a poor prognosis (15). There are >1 million newly diagnosed cases of male breast cancer each year, and breast cancer results in ~520,000 mortalities each year worldwide (16).…”

Section: Discussionmentioning

confidence: 99%

miR‑455‑5p promotes cell invasion and migration in breast cancer

2017

View full text Add to dashboard Cite

MicroRNA (miR)‑455‑5p has been identified as a biomarker for various types of cancer and may therefore be involved in the regulation of cancer development and progression. However, the specific role and function of miR‑455‑5p in breast cancer remains unclear. The present study explored the expression levels and function of miR‑455‑5p in breast cancer. The results from reverse transcription‑quantitative polymerase chain reaction analysis revealed that miR‑455‑5p was significantly upregulated in breast cancer. Clinically, increased expression of miR‑455‑5p predicted a poor survival rate and miR‑455‑5p was identified as one of the independent prognostic factors for breast cancer patients. Furthermore, results from wound healing and Transwell assays revealed that miR‑455‑5p accelerated invasiveness and migration capabilities of breast cancer cells. In addition, programmed cell death 4 was identified as a downstream target of miR‑455‑5p and its expression was observed to be negatively regulated by miR‑455‑5p. Overall, miR‑455‑5p may function as an oncogene in breast cancer, and may therefore be used as a prognostic marker for breast cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

miR‑455‑5p promotes cell invasion and migration in breast cancer

2017

View full text Add to dashboard Cite

show abstract

“…Radiolabelled variants of these agents can act as probes for the detection of target cells through SPECT and PET scanners. Several radiolabelled peptides, cytokines and mAb are used for imaging tumours and inflammation and infection, with the intention to improve the monitoring of the efficacy of new biological therapies [7]. A nuclear medicine approach will have the advantage of not being invasive respect to other techniques such as biopsy, colonoscopy and others.…”

Section: Can Nuclear Medicine Provide a Rationale For Starting Biologmentioning

confidence: 99%

Immunoscintigraphy for Therapy Decision Making and Follow - Up of Biological Therapies

Galli¹

2016

Int. J. Nucl. Medi. Res.

View full text Add to dashboard Cite

With the availability of new biological therapies there is the need of more accurate diagnostic tools to noninvasively assess the presence of their targets. In this scenario nuclear medicine offers many radiopharmaceuticals for SPECT or PET imaging of many pathological conditions. The availability of monoclonal antibodies provides tools to target specific antigens involved in angiogenesis, cell cycle or modulation of the immune systems. The radiolabelling of such therapeutic mAbs is a promising method to evaluate the antigenic status of each cancer lesion or inflamed sites before starting the therapy. It may also allow to perform follow-up of such biological therapies. In the present review we provide an overview of the most studied radiolabelled antibodies for therapy decision making and follow-up of patients affected by cancer and other pathological conditions.

show abstract

“…Molecular imaging with positron emission tomography/Xray computed tomography using the radiotracer 2-deoxy-2-[ 18 F]fluoro-D-glucose ([ 18 F]FDG PET/CT) allows the noninvasive detection, quantification, and visualization of tumor glycolysis [15,16]. Due to this advantage, [ 18 F]FDG PET/CT has been established as a valuable tool for staging, neo-/ adjuvant and palliative therapy monitoring, and follow-up of breast cancer patients [15,[17][18][19][20][21][22][23][24][25][26][27][28][29][30][31].…”

Section: Introductionmentioning

confidence: 99%

PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2− Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT

et al. 2019

View full text Add to dashboard Cite

Purpose: In PIK3CA mutant breast cancer, downstream hyperactivation of the PI3K/AKT/mTOR pathway may be associated with increased glycolysis of cancer cells. The purpose of this study was to investigate the functional association of PIK3CA mutational status and tumor glycolysis in invasive ER+/HER2− early breast cancer. Procedures: This institutional review board-approved retrospective study included a dataset of 67 ER+/HER2− early breast cancer patients. All patients underwent 2-deoxy-2-[ 18 F]fluoro-Dglucose positron emission tomography/X-ray computed tomography ([ 18 F]FDG PET/CT) and clinico-pathologic assessments as part of a prospective study. For this retrospective analysis, pyrosequencing was used to detect PIK3CA mutations of exons 4, 7, 9, and 20. Tumor glucose metabolism was assessed semi-quantitatively with [ 18 F]FDG PET/CT using maximum standardized uptake values (SUV max). SUV max values were corrected for the partial volume effect, and metabolic tumor volume was calculated using the volume of interest automated lesion growing function 2D tumor size, i.e., maximum tumor diameter was assessed on concurrent pretreatment contrast-enhanced magnetic resonance imaging. Results: PIK3CA mutations were present in 45 % of all tumors. Mutations were associated with a small tumor diameter (p G 0.01) and with low nuclear grade (p = 0.04). Glycolytic activity was positively associated with nuclear grade (p = 0.01), proliferation (p = 0.002), regional lymph node metastasis (p = 0.015), and metabolic tumor volume (p = 0.001) but not with tumor size/T-stage. Heinrich Magometschnigg and Katja Pinker as well as Peter Dubsky and Martin Filipits contributed equally to this work.

show abstract

PET/CT Imaging for Monitoring Recurrence and Evaluating Response to Treatment in Breast Cancer

Cited by 21 publications

References 34 publications

miR‑455‑5p promotes cell invasion and migration in breast cancer

miR‑455‑5p promotes cell invasion and migration in breast cancer

Immunoscintigraphy for Therapy Decision Making and Follow - Up of Biological Therapies

PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2− Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT

Contact Info

Product

Resources

About